Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Oncology

FDA decisions expected this month: stroke prevention, GIST and more

Close-up of vaccines, syringe, and stethoscope on a reflective surface in a clinical setting.

Several regulatory decisions are scheduled in the United States in November 2026. Among them is asundexian, an oral factor XIa inhibitor under priority review for secondary stroke prevention.

Decisions are also expected on treatments for myasthenia gravis, primary biliary cholangitis, breast cancer, and on bezuclastinib combined with sunitinib for gastrointestinal stromal tumours (GIST) after imatinib.

Source: Endocrinology Advisor